Atea Pharmaceuticals Inc logo

AVIR - Atea Pharmaceuticals Inc Share Price

$13.24 -0.6  -4.2%

Last Trade - 20/10/21

Mid Cap
Market Cap £829.3m
Enterprise Value £237.4m
Revenue £126.9m
Position in Universe 2870th / 7242
Unlock AVIR Revenue
Relative Strength (%)
1m -48.8%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -85.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 48.6 287.7 2,840
+295.3 +2,590
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2021, AteaPharmaceuticals Inc revenues increased from $0K to $126.4M.Net income totaled $32.3M vs. loss of $14M. Revenuesreflect an increase in demand for the Company's productsand services due to favorable market conditions. Net Incomereflects Interest income and other, net increase of 64% to$110K (income). Basic Earnings per Share excludingExtraordinary Items increased from -$0.17 to $0.39.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


AVIR Revenue Unlock AVIR Revenue

Net Income

AVIR Net Income Unlock AVIR Revenue

Normalised EPS

AVIR Normalised EPS Unlock AVIR Revenue

PE Ratio Range

AVIR PE Ratio Range Unlock AVIR Revenue

Dividend Yield Range

AVIR Dividend Yield Range Unlock AVIR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
AVIR EPS Forecasts Unlock AVIR Revenue
Profile Summary

Atea Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. It is focused on development of product candidates to treat coronavirus disease (COVID-19), dengue, chronic hepatitis C (HCV), and respiratory syncytial virus (RSV). Its purine nucleotide prodrug platform develops treatments for life threatening diseases caused by single stranded ribonucleic acid (ssRNA) viral infections. Its lead product candidate, AT-527, is an orally administered, antiviral agent for the treatment of patients with COVID-19. It is developing AT-752, an oral, purine nucleoside prodrug product candidate for the treatment of dengue. It is also developing AT-787 for the treatment of chronic HCV infection, including patients with decompensated cirrhosis. It is evaluating AT-889 and other candidates for the treatment of RSV.

Last Annual December 31st, 2020
Last Interim June 30th, 2021
No. of Shareholders: 144
No. of Employees: 49
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 82,776,937
Free Float (0.0%)
Eligible for
AVIR Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for AVIR
Upcoming Events for AVIR
Frequently Asked Questions for Atea Pharmaceuticals Inc
What is the Atea Pharmaceuticals Inc share price?

As of 20/10/21, shares in Atea Pharmaceuticals Inc are trading at $13.24, giving the company a market capitalisation of £829.3m. This share price information is delayed by 15 minutes.

How has the Atea Pharmaceuticals Inc share price performed this year?

Shares in Atea Pharmaceuticals Inc are currently trading at $13.24 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Atea Pharmaceuticals Inc price has moved by % over the past year.

What are the analyst and broker recommendations for Atea Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Atea Pharmaceuticals Inc, there are there are currently 2 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Atea Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Atea Pharmaceuticals Inc next release its financial results?

Atea Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the Atea Pharmaceuticals Inc dividend yield?

Atea Pharmaceuticals Inc does not currently pay a dividend.

Does Atea Pharmaceuticals Inc pay a dividend?

Atea Pharmaceuticals Inc does not currently pay a dividend.

When does Atea Pharmaceuticals Inc next pay dividends?

Atea Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Atea Pharmaceuticals Inc shares?

To buy shares in Atea Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Atea Pharmaceuticals Inc?

Shares in Atea Pharmaceuticals Inc are currently trading at $13.24, giving the company a market capitalisation of £829.3m.

Where are Atea Pharmaceuticals Inc shares listed? Where are Atea Pharmaceuticals Inc shares listed?

Here are the trading details for Atea Pharmaceuticals Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: AVIR
What kind of share is Atea Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Atea Pharmaceuticals Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Atea Pharmaceuticals Inc share price forecast 2021?

Shares in Atea Pharmaceuticals Inc are currently priced at $13.24. At that level they are trading at 0.325% discount to the analyst consensus target price of 0.00.

Analysts covering Atea Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of 0.58 for the next financial year.

How can I tell whether the Atea Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Atea Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -67.61%. At the current price of $13.24, shares in Atea Pharmaceuticals Inc are trading at -66.5% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Atea Pharmaceuticals Inc PE Ratio?

The Atea Pharmaceuticals Inc PE ratio based on its reported earnings over the past 12 months is 13.47. The shares are currently trading at $13.24.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Atea Pharmaceuticals Inc?

Atea Pharmaceuticals Inc's management team is headed by:

Jean-Pierre Sommadossi - CHM
Andrea Corcoran - CFO
Wayne Foster - SVF
Janet Hammond - OTH
Maria Horga - OTH
John Vavricka - OTH
Jerome Adams - DRC
Franklin Berger - LED
Bruno Lucidi - IND
Polly Murphy - IND
Barbara Duncan - IND
Who are the major shareholders of Atea Pharmaceuticals Inc?

Here are the top five shareholders of Atea Pharmaceuticals Inc based on the size of their shareholding:

Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 14.84% (12.3m shares)
Morningside Venture Investments, Ltd. Corporation
Percentage owned: 8.02% (6.63m shares)
Cormorant Asset Management, LP Hedge Fund
Percentage owned: 7.75% (6.41m shares)
JPM Partner LLC Corporation
Percentage owned: 7.16% (5.93m shares)
RA Capital Management, LP Hedge Fund
Percentage owned: 6.49% (5.37m shares)
Similar to AVIR
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.